SABCS: New Endocrine Therapy, Giredestrant, Cuts Breast Cancer Recurrence

TUESDAY, Dec. 16, 2025 – Giredestrant, a selective estrogen receptor antagonist and degrader given as an adjuvant therapy, shows significant improvement in invasive disease-free survival (iDFS) in patients with early-stage, hormone receptor...